Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 103

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 103
---
 our stock could decline.
If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn
could cause our stock price to decline.

The
price of our securities may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of
our securities.

The
market price of our securities is likely to be highly volatile due to many factors, including:

    ●
    our ability to successfully
    proceed to and conduct clinical trials;

    ●
    results of pre-clinical
    and clinical trials of our existing lead or new future compounds or those of our competitors;

    ●
    the success of competitive
    products or technologies;

    ●
    commencement or
    termination of collaborations;

    ●
    regulatory or legal
    developments in the United States and other countries;

    ●
    developments or
    disputes concerning patent applications, issued patents or other proprietary rights;

    ●
    the recruitment
    or departure of key personnel;

    ●
    the level of expenses
    related to any of our current or future compounds or clinical development programs;

    ●
    the results of our
    efforts to discover, develop, acquire or in-license additional new compounds;

    ●
    actual or anticipated
    changes in estimates as to financial results, development timelines or recommendations by securities analysts;

    ●
    our inability to
    obtain or delays in obtaining adequate product supply for any approved product or inability to do so at acceptable prices;

    ●
    disputes or other
    developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection
    for our technologies;

    ●
    significant lawsuits,
    including patent or stockholder litigation;

    ●
    variations in our
    financial results or those of companies that are perceived to be similar to us;

    ●
    changes in the structure
    of healthcare payment systems;

    ●
    market conditions
    in the pharmaceutical and biotechnology sectors;

    ●
    general economic,
    industry and market conditions; and

    ●
    the other factors
    described in this “Risk Factors” section.

60 

The
stock markets have experienced extreme volatility in recent years that has been unrelated to operating performance. These broad
market fluctuations may adversely affect the trading price of our securities. In the past, following periods of volatility in
the market price of a company’s securities, class action litigation has often